Oric Pharmaceuticals Inc ORIC:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/01/21 EST
35.67quote price arrow up+3.27 (+10.09%)
Volume
190,428
52 week range
18.60 - 40.81

...

Loading . . .

KEY STATS

  • Open32.68
  • Day High36.65
  • Day Low32.68
  • Prev Close35.67
  • 52 Week High40.81
  • 52 Week High Date12/18/20
  • 52 Week Low18.60
  • 52 Week Low Date09/21/20
  • Market Cap1.27B
  • Shares Out35.59M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.59
  • P/E (TTM)-22.47
  • Fwd P/E (NTM)-18.10
  • EBITDA (MRQ)-40.698M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Oric Pharmaceuticals Inc News

There is no recent news for this security.

Latest ORIC News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and...
Richard Heyman Ph.D.
Chairman
Jacob Chacko M.D.
Chief Executive Officer
Dominic Piscitelli CPA
Chief Financial Officer
Christian Kuhlen M.D., Esq.
General Counsel
Address
240 E. Grand Ave., 2nd Floor
South San Francisco, CA
94080
United States